Warren Botnick, MD
Pulmonary Disease · Natchitoches, LANPI 1750382339
Payments from drug & device makers
Across 612 payments — averaging $367.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$148K
- Mylan Specialty L.p.$42K
- Viatris Specialty LLC$25K
- Sanofi$2K
- AstraZeneca$2K
- Jazz Pharmaceuticals Inc.$1K
- plus $5K from 21 others
Across 9 payments — averaging $168.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 237 | $148,312 |
| Mylan Specialty L.p. | 78 | $41,987 |
| Viatris Specialty LLC | 24 | $24,745 |
| Sanofi | 13 | $1,767 |
| AstraZeneca | 84 | $1,726 |
| Jazz Pharmaceuticals Inc. | 4 | $1,103 |
| Hill-rom Company, Inc | 1 | $875 |
| Amgen | 4 | $601 |
| Viiv Healthcare Company | 1 | $600 |
| Baxter Healthcare | 32 | $517 |
| Regeneron Healthcare Solutions, Inc. | 22 | $501 |
| Boehringer Ingelheim | 32 | $492 |
| Bayer | 14 | $439 |
| Advanced Respiratory, Inc | 15 | $283 |
| Insmed, Inc. | 7 | $219 |
| Genentech USA, Inc. | 9 | $174 |
| Grifols USA, LLC | 7 | $124 |
| Electromed, Inc. | 6 | $91 |
| Sunovion Pharmaceuticals Inc. | 8 | $90 |
| Teva Pharmaceuticals USA, Inc. | 3 | $62 |
| Philips North America LLC | 2 | $49 |
| Gilead | 3 | $46 |
| Merck | 2 | $41 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Itamar Medical Inc | 1 | $9 |
How this compares
$224,906 in reported general payments places this provider in the 90th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Natchitoches
- David GreenShreveport$2M
- Joseph LaskyNew Orleans$1.9M
- Leonardo SeoaneNew Orleans$1.6M
- Ross KlingsbergNew Orleans$1.2M
- Juzar AliNew Orleans$775K
- Hollis O NealBaton Rouge$682K
- Andrea EspinozaHouma$655K
- Ramsy AbdelghaniNew Orleans$474K
- Bennett DeboisblancNew Orleans$457K
- Nereida ParadaNew Orleans$289K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.